0.9784
price up icon0.38%   0.0037
after-market 시간 외 거래: .94 -0.0384 -3.92%
loading
전일 마감가:
$0.9747
열려 있는:
$1
하루 거래량:
6.03M
Relative Volume:
0.72
시가총액:
$12.82M
수익:
-
순이익/손실:
$-7.51M
주가수익비율:
-0.7412
EPS:
-1.32
순현금흐름:
$-8.02M
1주 성능:
-4.08%
1개월 성능:
+6.84%
6개월 성능:
+18.16%
1년 성능:
-28.58%
1일 변동 폭
Value
$0.9138
$1.05
1주일 범위
Value
$0.9138
$1.05
52주 변동 폭
Value
$0.58
$3.80

Hoth Therapeutics Inc Stock (HOTH) Company Profile

Name
명칭
Hoth Therapeutics Inc
Name
전화
(646)756-2997
Name
주소
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Name
직원
3
Name
트위터
Name
다음 수익 날짜
2024-11-11
Name
최신 SEC 제출 서류
Name
HOTH's Discussions on Twitter

HOTH을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
HOTH
Hoth Therapeutics Inc
0.9784 12.82M 0 -7.51M -8.02M -1.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2019-10-15 개시 The Benchmark Company Speculative Buy

Hoth Therapeutics Inc 주식(HOTH)의 최신 뉴스

pulisher
09:58 AM

Hoth Flat on Hookup with Washington Univ. - Baystreet.ca

09:58 AM
pulisher
09:03 AM

Hoth Therapeutics reports Alzheimer’s drug candidate success - Investing.com India

09:03 AM
pulisher
08:02 AM

Breakthrough: New Alzheimer's Drug Cuts Key Brain Marker by 15%University Study Reveals - Stock Titan

08:02 AM
pulisher
07:59 AM

Hoth Therapeutics Plans To Advance HT-ALZ Into Clinical Development - MarketScreener

07:59 AM
pulisher
07:58 AM

Revolutionary Alzheimer's Treatment Cuts Brain Amyloid by 15% in Just 20 Hours - Stock Titan

07:58 AM
pulisher
Apr 01, 2025

Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Hoth Therapeutics receives USPTO filing receipt for HT-001 patent application - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

New Patent Filing Strengthens Hoth's Cancer Treatment IP PortfolioKey Details - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Hoth Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

Hoth Therapeutics Inc. (HOTH) reports earnings - Quartz

Mar 28, 2025
pulisher
Mar 28, 2025

Hoth Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 28, 2025
pulisher
Mar 26, 2025

Hoth Therapeutics enhances patent claims, begins toxicity study By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Hoth Therapeutics enhances patent claims, begins toxicity study - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Major Progress: Hoth's Cancer-Fighting Drug Secures Patent Protection and Launches Critical Safety Study - Stock Titan

Mar 26, 2025
pulisher
Mar 24, 2025

Hoth Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView

Mar 24, 2025
pulisher
Mar 20, 2025

Hoth Therapeutics (HOTH) Projected to Post Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Balance Sheet Breakdown: Hoth Therapeutics Inc (HOTH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Mar 19, 2025
pulisher
Mar 19, 2025

Hoth Therapeutics announces ‘positive’ results from study of HT-KIT - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

Hoth reports progress in GIST treatment with HT-KIT By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Hoth reports progress in GIST treatment with HT-KIT - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment - PR Newswire

Mar 18, 2025
pulisher
Mar 18, 2025

Revolutionary 24-Hour Cancer Treatment Success: Hoth's HT-KIT Destroys GIST Tumors in Breakthrough Study - Stock Titan

Mar 18, 2025
pulisher
Mar 17, 2025

Short Interest in Hoth Therapeutics, Inc. (NASDAQ:HOTH) Decreases By 24.8% - Defense World

Mar 17, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics to submit HT-001 expanded access application By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics Announces Plans To Submit Expanded Access Application For Ht-001 To Support Cancer Patients In Need - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Dips on Drug Application - Baystreet.ca

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics to submit Expanded Access application for HT-001 - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics to submit HT-001 expanded access application - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need - PR Newswire

Mar 10, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics reports HT-001 cream success in skin toxicity By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics reports HT-001 cream success in skin toxicity - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting - PR Newswire

Mar 05, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics’ (HOTH) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Hoth Therapeutics Announces Positive Findings On GDNF's Potential As A Game-Changer In Obesity Treatment And Reduced Fatty Liver Disease - MarketScreener

Mar 04, 2025
pulisher
Mar 04, 2025

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease - PR Newswire

Mar 04, 2025
pulisher
Mar 04, 2025

GDNF shows promise in obesity treatment, Hoth research finds - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Financial Contrast: Emmaus Life Sciences (OTCMKTS:EMMA) and Hoth Therapeutics (NASDAQ:HOTH) - Defense World

Mar 04, 2025
pulisher
Feb 17, 2025

HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal - MSN

Feb 17, 2025
pulisher
Feb 12, 2025

Hoth Therapeutics (NASDAQ:HOTH) Given Buy Rating at D. Boral Capital - Defense World

Feb 12, 2025
pulisher
Feb 10, 2025

Hoth Therapeutics to Present at the LD Micro Main Event (XII) - ACCESS Newswire

Feb 10, 2025
pulisher
Feb 10, 2025

What to expect from HOTH’s earnings report this quarter? - US Post News

Feb 10, 2025
pulisher
Feb 10, 2025

Hoth Therapeutics, OnTargetx R&D Partner to Advance Research for Cancer Therapeutic - Contract Pharma

Feb 10, 2025
pulisher
Feb 10, 2025

HOTH's Cancer Breakthrough: Strategic Alliance Accelerates Novel HT-KIT Therapeutic Research - StockTitan

Feb 10, 2025
pulisher
Feb 08, 2025

Hoth Therapeutics expands at-the-market offering by $5 million - Investing.com Australia

Feb 08, 2025
pulisher
Jan 27, 2025

Research Analysts Set Expectations for HOTH FY2024 Earnings - Defense World

Jan 27, 2025
pulisher
Jan 26, 2025

Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at HC Wainwright - Defense World

Jan 26, 2025
pulisher
Jan 25, 2025

Hoth Therapeutics Regains Compliance with Nasdaq Listing RequirementsNew York, NY – January 24, 2025 – Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced today that it has successfully regained compliance with the minimum bid price requirement s - Defense World

Jan 25, 2025

Hoth Therapeutics Inc (HOTH) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
자본화:     |  볼륨(24시간):